The Biopharma Pod

William Reed Ltd
  • 0,0 (0)
  • Actualité économique

Brought to you by the team behind BioPharma-Reporter.com

  1. 16/10/2023

    Podcast: The British start-up taking psychedelic therapy mainstream

    In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.

    29 min

  2. 22/07/2021

    What kind of consistency can industry expect from the FDA post pandemic?

    How the US Food and Drug Administration (FDA) exercises flexibility has been an important and emerging issue for the past several years.

    15 min

  3. 17/05/2021

    Chicago emerging as a life science and biopharma hub

    Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.

    15 min

  4. 07/05/2021

    Will Biden backed bills boost biosimilars uptake in the US?

    Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.

    9 min

  5. 15/08/2017

    Bioproduction bottlenecks increasing due to staff shortages, says report

    A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.

    4 min

  6. 30/10/2013

    'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

    Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.

    6 min

  7. 15/10/2013

    Better single-use cross flow techs still needed says GE Healthcare

    The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.

    3 min

  8. 16/07/2013

    Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech

    Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.

    5 min
Tout afficher (18)

À propos

Brought to you by the team behind BioPharma-Reporter.com

Informations

  • Création
    William Reed Ltd
  • Années d’activité
    2017 - 2023
  • Épisodes
    18
  • Classification
    Tous publics
  • Copyright
    ℗ & © William Reed Ltd
  • Site web de l’émission
    The Biopharma Pod